Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05427084 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Canagliflozin Targeting Vascular Inflammation

Study acronym: CANTORSING
StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2025 to Dec 2026v6
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2024 to Nov 15, 2024
    • Study completion date: Dec 2025 to Dec 2026
    • Site details revised
    v5
  3. Primary completion date: Dec 2024 to Dec 2025
    • Start date: Dec 2023 to May 2024
    • Study sites: 0 to 1
    • Study completion date: Jun 2025 to Dec 2025
    v4
  4. Start date: Sep 2023 to Dec 2023v3
  5. Start date: Sep 2022 to Sep 2023
    • Primary completion date: Sep 2024 to Dec 2024
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ottawa Heart Institute Research Corporation
92 trials monitored
See 5 trials at risk
Heart Disease
8,786 trials monitored
See 412 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
and 1 more disease
CANTOR SING is a pilot single center double blinded randomized study. The investigators will compare the effect of canagliflozin (300 mg daily - intervention arm) vs. placebo (control group) on the FDG aortic uptake in patients with stable CAD (over 60 days post-myocardial infarction) after a 6-month period of treatment. The investigators plan to enroll 8 patients in each arm (total sample size: 16 patients). Primary endpoint is the change in FDG aortic uptake between baseline and 6 months in each arm.
Trial Details
NCT Number NCT05427084
Lead Sponsor Ottawa Heart Institute Research Corporation
Conditions
(from sponsor)		 Diabetes Type 2, Coronary Artery Disease
Related terms Coronary Artery Disease, Diabetes Mellitus, Type 2
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov